918 related articles for article (PubMed ID: 19808133)
1. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
[TBL] [Abstract][Full Text] [Related]
2. The clinical tolerability profile of alendronate.
Watts N; Freedholm D; Daifotis A
Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
[TBL] [Abstract][Full Text] [Related]
3. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
[TBL] [Abstract][Full Text] [Related]
6. The antifracture efficacy of alendronate.
Seeman E
Int J Clin Pract Suppl; 1999 Apr; 101():40-5. PubMed ID: 12675021
[TBL] [Abstract][Full Text] [Related]
7. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
8. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
[TBL] [Abstract][Full Text] [Related]
10. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
Bauer DC; Black D; Ensrud K; Thompson D; Hochberg M; Nevitt M; Musliner T; Freedholm D
Arch Intern Med; 2000 Feb; 160(4):517-25. PubMed ID: 10695692
[TBL] [Abstract][Full Text] [Related]
11. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
12. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A
Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969
[TBL] [Abstract][Full Text] [Related]
13. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
Binkley N; Ringe JD; Reed JI; Ljunggren O; Holick MF; Minne HW; Liu M; Lamotta A; West JA; Santora AC
Bone; 2009 Apr; 44(4):639-47. PubMed ID: 19185560
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
15. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
17. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
[TBL] [Abstract][Full Text] [Related]
18. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
[TBL] [Abstract][Full Text] [Related]
19. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.
Cryer B; Miller P; Petruschke RA; Chen E; Geba GP; Papp AE
Aliment Pharmacol Ther; 2005 Mar; 21(5):599-607. PubMed ID: 15740544
[TBL] [Abstract][Full Text] [Related]
20. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
